Can a Dual-Action pill tame bone marrow tumors?

NCT ID NCT05115344

Terminated Disease control Sponsor: Guizhou Bailing Group Pharmaceutical Co Ltd Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This phase 1 trial is testing an experimental pill called flonoltinib maleate in people with certain bone marrow tumors, including myelofibrosis, polycythemia vera, and essential thrombocythemia. The drug targets two proteins involved in abnormal blood cell growth. The study aims to find the safest dose and see how the body processes the drug, while also checking for early signs of benefit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: flonoltinib maleate tablets
What this could lead to: If successful, this could lead to a new oral treatment option for myeloproliferative neoplasms, potentially offering better selectivity and fewer side effects than existing JAK inhibitors.
What could go wrong: This is an early-phase dose-escalation study, so safety and effectiveness are not yet established. The drug may not show sufficient benefit or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL THROMBOCYTHEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera essential thrombocythemia myelofibrosis Myeloproliferative Disorders myeloproliferative neoplasm primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS，MF MYELOPROLIFERATIVE NEOPLASM (MPN)

More trials for these conditions

Other studies related to the condition(s) this trial covers.